CybernaX Biotechnologies
Targeted lipid nanoparticles, each carrying nucleic acid cargo and displaying surface targeting binders, approaching and entering a cell.

Nucleic acid deliveryis at the core ofeverything we do.

Explore the platform → Partner with us
The CybernaX delivery platforms

Two lipid platformsfor next generation non-viral delivery.

ELITE (CX Ionizable Lipid) — Embodied Lipid Intelligence for Targeted Expression.

Embodied-AI screened ionizable lipid library that balances high potency and a good safety profile.

ENDURE (CX Stabilizing Lipid) — Engineered Non-immunogenic Defined, Uniform lipid for Repeat Exposure.

A PEG-free monodisperse lipid built for long-term repeat dosing.

  • High efficacy
  • Low toxicity
  • Tissue tropism
  • High robustness
  • Lipid CMC scalable
  • Repeat-dosing ready
  • Recognized FTO
Where non-viral delivery stalls today

Two problems hold back almost every program.

We built one platform for each of them.

LOW EFFICACY cell membrane Early endosome Late endosome Lysosome Minimal trafficking to the cytosol — the payload is degraded before it can act. >98% never escapes SYSTEMIC TOXICITY HIGH DOSE to compensate ALT / AST TBIL CK IL-6 / TNF-α IFN-γ / MCP-1 Liver, cardiac and cytokine markers all rise together with dose.
Problem 01

The balance between toxicity and efficacy.

More than 98% of delivered RNA is trapped in endosomes and degraded. The classic fix is a more disruptive lipid or a higher dose, and both buy efficacy at the cost of tolerability — liver, cardiac and cytokine markers rise, and the dose ceiling comes down. Extrahepatic targeting is harder still, because ApoE coats the particle and sends it to the liver.

How ELITE (CX Ionizable Lipid) solves it →

Dose 1 Dose 5 Expression PEG-lipid CX Stabilizing Lipid anti-PEG antibodies
Problem 02

PEG-lipids provoke antibodies, so the second, third and fifth dose stop working.

Pre-existing and treatment-induced anti-PEG antibodies bind the PEGylated component, trigger complement activation and drive accelerated blood clearance and pseudoallergic reactions. For any chronic indication that needs repeat dosing, this is a ceiling on the whole modality.

How ENDURE (CX Stabilizing Lipid) solves it →

Next big modality

Partner with us to clear the obstacles in non-viral delivery — and advance xNA-LNP as the next major modality.

Licensing, proof-of-concept material transfer or research collaboration — we shape the engagement around your programs and pipelines.

Start a conversation →

Partnering with us

Tell us your target tissue, payload and mechanism of action. We will tell you which lipid chemistry gets you there.

info@cybernaxbio.com